TABRECTA® (capmatinib) tablets is the first treatment specifically for patients with METex14-positive mNSCLC
Novartis Patient Support™
Now that you have made the decision to prescribe TABRECTA, Novartis Patient Support is a program designed to help your eligible patients start, stay, and save on TABRECTA. To learn more, call 1-800-282-7630.
Universal Co-pay Program
Novartis Oncology Universal Co-pay Program
Patients may be eligible for immediate co-pay savings on their next prescription of TABRECTA.
Eligible patients with private insurance may pay $0 per month
Novartis will pay the remaining co-pay, up to $15,000 per calendar year, per product*
Encourage your patients to find out if they are eligible to enroll in the Novartis Oncology Universal Co-pay Program by visiting Copay.NovartisOncology.com or calling 1-877-577-7756.
METex14, MET exon 14 skipping; mNSCLC, metastatic non-small cell lung cancer.
*Limitations apply. This offer is only available to patients with private insurance. The program is not available for patients who are enrolled in Medicare, Medicaid, or any other federal or state health care program. Novartis reserves the right to rescind, revoke, or amend this program without notice. For full Terms and Conditions, visit Copay.NovartisOncology.com or call 1-877-577-7756.